## Abstract There is no effective therapy for human T‐cell lymphotropic virus type I (HTLV‐I)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP). Glucocorticoids are effective to reduce the motor disability in these patients, but its role as anti‐spastic drugs is unknown. Here it is repor
Tax Posttranslational Modifications and Interaction with Calreticulin in MT-2 Cells and Human Peripheral Blood Mononuclear Cells of Human T Cell Lymphotropic Virus Type-I-Associated Myelopathy/Tropical Spastic Paraparesis Patients
✍ Scribed by Medina, Fernando; Quintremil, Sebastian; Alberti, Carolina; Barriga, Andres; Cartier, Luis; Puente, Javier; Ramírez, Eugenio; Ferreira, Arturo; Tanaka, Yuetsu; Valenzuela, Maria Antonieta
- Book ID
- 126907232
- Publisher
- Mary Ann Liebert
- Year
- 2014
- Tongue
- English
- Weight
- 441 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0889-2229
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Human T‐cell lymphotropic virus type I (HTLV‐I) is the etiologic agent of HTLV‐I‐associated myelopathy/tropical spastic paraparesis (HAM/TSP). High HTLV‐I provirus load and __tax__ mRNA level have been suggested as predictors of disease progression in patients with HAM/TSP, but little i
## Abstract We searched for the presence of human T‐cell leukemia virus type I (HTLV‐I) sequences in central nervous system and muscle lesions of 3 patients with tropical spastic paraparesis/HTLV‐I—associated myelopathy (TSP/HAM) and 3 patients with HTLV‐I—associated polymyositis. Proviral DNA codi